10x Genomics, Inc. (TXG) Fair Value 2026

TXG · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

7.6 /10

32 fundamental signals · 5 models active

Value Trap Risk

SAFE (13/100)

Quick Summary — As of 2026-10-07, 10x Genomics, Inc. (TXG) trades at $80.66, versus a $6.99 median fair value across its 5 active models — 91.3% below the current price. QOC: 7.6/10. Value Trap Risk: 13/100 (SAFE). 5/13 models active. Within that set, the Bayesian DCF component alone returns $6.99.

Key Facts

Ticker
TXG
Price
$80.66
Quality Score
7.6/10
Value Trap Risk
13/100
Models Active
5/13
Last Updated
Strength: 5 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is 10x Genomics, Inc. (TXG) Undervalued or Overvalued in 2026?

According to CirclFi’s 5-model valuation engine, 10x Genomics, Inc. (TXG) appears overvalued as of : the median of 5 independent fair value estimates is $6.99, 91.3% below the current price of $80.66. Estimates range from $2.69 to $14.03. TXG scores 7.6/10 on fundamental quality and 13/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -20.1% versus its own 13-model consensus, across 3,777 rated companies as of 2026-10-07. TXG’s -91.3% gap is wider than that market norm, and the Medical Devices sector median is -41.5%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy 10x Genomics, Inc. Stock in 2026? →

What Fair Value Does Each Model Give TXG?

5 Intrinsic Value Models vs. Current Price ($80.66)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $6.99 -91.3%
Ensemble · Low Conviction
 $7.11 -91.2%
Unlock the Full Matrix

Access 3 additional models including Regime Cross-Sectional, FTNN Topology, and more.

$2 / day

Billed monthly ($60/mo) or annually ($299/yr)

Unlock All 5 Models →

Cancel anytime · No contracts · Instant access

What Is TXG's Fair Value Range?

Spread across 5 independent models · $2.69 to $14.03

CirclFi's 5 active models place 10x Genomics, Inc. (TXG) between $2.69 and $14.03 per share, a spread of 162% of the median. The median of that range — $6.99 — is the fair value CirclFi publishes for TXG, against a current price of $80.66.

Low · Regime CrossHigh · FTNN
$2.69median $6.99$14.03
Where the range comes from
Most bearish modelRegime Cross-Sectional$2.69
Most bullish modelFTNN Topology$14.03
Model agreement0 bullish · 5 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for TXG. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on TXG, not a CirclFi price target. How each model works →

What Is 10x Genomics, Inc. (TXG) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, 10x Genomics, Inc.'s intrinsic value is estimated at $6.99, suggesting the stock is overvalued at its current price of $80.66. With 5 out of 5 models flagging downside (-91.3% vs price), the market may be pricing in unsustainable growth.

What Do the Models Say About TXG?

5 of 13 models are currently active for TXG. All 5 active models suggest the stock trades above fair value. Taken together, their median fair value for TXG is $6.99 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $6.99 on its own, implying -91.3% downside from the current price. See which stocks rank higher →

How Does TXG Rank in Medical Devices?

Among 161 Medical Devices stocks, TXG ranks #33 by Quality of Company score. CirclFi's QOC score of 7.6/10 evaluates 32 fundamental signals. A score of 7.6 indicates above-average quality.

See all Most Undervalued Medical Devices Stocks →

Within the Medical Devices space, 10x Genomics, Inc. competes in an environment where R&D productivity ratio often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is TXG a Value Trap?

CirclFi's Value Trap algorithm assigns TXG a score of 13/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

5 of 13 models are active for 10x Genomics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, 10x Genomics, Inc.'s fundamental quality profile registers 7.6/10. This robust score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

Models cluster within a tight range (+14.1% spread), increasing conviction. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every TXG valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across TXG's 5 active models, average confidence is 37%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy 10x Genomics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

BIOBio-Rad Laboratories, Inc.QOC 7.8AXGNAxogen, Inc.QOC 7.6MDTMedtronic plcQOC 7.8BRKRBruker CorporationQOC 7.5GEHCGE HealthCare Technologies Inc.QOC 7.9SIBNSI-BONE, Inc.QOC 7.5TNDMTandem Diabetes Care, Inc.QOC 6.5NXLNexalin Technology, Inc.QOC 5.6ODYYOdyssey Health, Inc.QOC 3.7IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: BIO · AXGN · MDT · BRKR · GEHC · SIBN · TNDM · NXL · ODYY · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to TXG?

7 companies across all industries closest to TXG’s Quality of Company score of 7.6/10.

LFUSLittelfuse, Inc.QOC 7.6VTSIVirTra, Inc.QOC 7.6GBTGGlobal Business Travel Group, Inc.QOC 7.6ACCSACCESS Newswire Inc.QOC 7.6RDNRadian Group Inc.QOC 7.6NPNeptune Insurance Holdings Inc.QOC 7.6NVDANVIDIA CorporationQOC 10.0

Read investment analysis: LFUS · VTSI · GBTG · ACCS · RDN · NP · NVDA

Where Does TXG Sit in CirclFi's Medical Devices Rankings?

TXG is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About 10x Genomics, Inc.’s Valuation?

What is 10x Genomics, Inc.'s intrinsic value in 2026?

CirclFi puts 10x Genomics, Inc. (TXG)'s intrinsic value at $6.99 — the median of 5 independent model estimates as of 2026-10-07, ranging from $2.69 to $14.03. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $6.99 on its own. The Quality of Company score is 7.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is TXG overvalued or undervalued right now?

At $80.66, 0 of 5 active models suggest TXG may be undervalued, while 5 indicate potential overvaluation. The median of all 5 fair value estimates is $6.99, 91.3% below the current price of $80.66 — a consensus view that TXG is overvalued. The assessment depends on which methodology best fits 10x Genomics, Inc.'s business model in Medical Devices.

What does a Quality of Company score of 7.6 mean for TXG?

10x Genomics, Inc.'s QOC of 7.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on TXG?

CirclFi analyzes TXG with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 5 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on TXG?

Of the 5 models currently active on TXG, FTNN Topology is the most bullish at $14.03 per share, and Regime Cross-Sectional is the most bearish at $2.69. CirclFi's published fair value for TXG is the median of that range, $6.99, not either extreme. The gap between the two ends equals 162% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is TXG a value trap in 2026?

10x Genomics, Inc.'s Value Trap score is 13/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 5-model valuation engine, 10x Genomics, Inc. (TXG) has a median fair value of $6.99 — 91.3% below the current price of $80.66 — as of 2026-10-07.” Source: circlfi.com/stock/TXG/ · Methodology
Primary sources for this TXG valuation
  • Financial statements: 10x Genomics, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001770787) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for TXG as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 5 mathematical frameworks give you clarity on TXG.

Unlock All 5 Fair Values — $60/mo

Cancel anytime · Less than a cup of coffee · Instant access

3 models hidden for TXG Unlock All 5 — $60/mo